Ovid Therapeutics(DE:1OT)
€2.480.00 (0.00%)
DE:1OT
Ovid Therapeutics stock forecast
€2.48
At close:0.00 (0.00%)
Ovid Therapeutics (1OT) Stock Forecast & Price Target
6 Followers
1OT Analyst Ratings
Strong Buy
7Buy0Hold0Sell
Based on 7 analysts giving stock ratings to Ovid Therapeutics in the past 3 months
1OT Stock 12 Month Forecast
Average Price Target
€5.10▲(105.68% Upside)Based on 7 Wall Street analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. The average price target is EUR 5.10 with a high forecast of EUR 6.33 and a low forecast of EUR 3.62. The average price target represents a 105.68% change from the last price of EUR 2.48.
Past 12 Months12 Month ForecastJan2026Oct2026
High€6.33
Average€5.10
Low€3.62
Highest Price TargetHighest€6.33Average Price Target€5.10Lowest Price TargetLowest€3.62
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Boobalan Pachaiyappan | Roth MKM | €7.23→€4.97 | buy | 100.47%Upside | Reiterated | 11/13/26 | ||
| Thomas Shrader | BTIG | €3.62 | buy | 45.80%Upside | Reiterated | 11/11/26 | ||
| Rudy Li | Wolfe Research | €4.52 | buy | 82.24%Upside | Initiated | 10/15/26 | ||
| Imogen Mansfield | Cantor Fitzgerald | €5.42 | buy | 118.69%Upside | Initiated | 10/09/26 | ||
| Laura Chico | Wedbush | €6.33 | buy | 155.14%Upside | Reiterated | 10/08/26 | ||
| Delma Caiati | Guggenheim | €6.33 | buy | 155.14%Upside | Initiated | 10/05/26 | ||
| Ram Selvaraju | H.C. Wainwright | €3.62→€4.52 | buy | 82.24%Upside | Reiterated | 09/11/26 | ||
| Kostas Biliouris | Oppenheimer | €8.14 | buy | 228.04%Upside | Reiterated | 08/14/26 | ||
| Francois Brisebois | LifeSci Capital | €4.52 | buy | 82.24%Upside | Reiterated | 08/14/26 | ||
| Myles Minter | William Blair | ― | buy | ― | Reiterated | 08/13/26 | ||
| Ritu Baral | TD Cowen | ― | buy | ― | Reiterated | 08/13/26 | ||
| Madison Elsaadi | B. Riley Securities | €4.52 | buy | 82.24%Upside | Reiterated | 05/13/26 | ||
| Marc Goodman | Leerink Partners | €4.52 | buy | 82.24%Upside | Initiated | 11/17/25 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Boobalan PachaiyappanRoth MKM | BuyReiterated€7.23→€4.97 | 11/13/26 | 100.47%Upside | ||
| Thomas ShraderBTIG | BuyReiterated€3.62 | 11/11/26 | 45.80%Upside | ||
| Rudy LiWolfe Research | BuyInitiated€4.52 | 10/15/26 | 82.24%Upside | ||
| Imogen MansfieldCantor Fitzgerald | BuyInitiated€5.42 | 10/09/26 | 118.69%Upside | ||
| Laura ChicoWedbush | BuyReiterated€6.33 | 10/08/26 | 155.14%Upside | ||
| Delma CaiatiGuggenheim | BuyInitiated€6.33 | 10/05/26 | 155.14%Upside | ||
| Ram SelvarajuH.C. Wainwright | BuyReiterated€3.62→€4.52 | 09/11/26 | 82.24%Upside | ||
| Kostas BiliourisOppenheimer | BuyReiterated€8.14 | 08/14/26 | 228.04%Upside | ||
| Francois BriseboisLifeSci Capital | BuyReiterated€4.52 | 08/14/26 | 82.24%Upside | ||
| Myles MinterWilliam Blair | BuyReiterated | 08/13/26 | ― | ||
| Ritu BaralTD Cowen | BuyReiterated | 08/13/26 | ― | ||
| Madison ElsaadiB. Riley Securities | BuyReiterated€4.52 | 05/13/26 | 82.24%Upside | ||
| Marc GoodmanLeerink Partners | BuyInitiated€4.52 | 11/17/25 | 82.24%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Ovid Therapeutics
3 Months
Success Rate6/8 ratings generated profit
75%
Average Return
+53.89%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +53.89% per trade.
1 Year
Success Rate6/8 ratings generated profit
75%
Average Return
+129.61%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +129.61% per trade.
2 Years
Success Rate14/17 ratings generated profit
82%
Average Return
+198.28%
Copying Thomas Shrader's trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +198.28% per trade.
1OT Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 7 | 5 | 6 | 10 | 7 |
| Buy | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 9 | 7 | 8 | 12 | 8 |
In the current month, 1OT has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1OT average Analyst price target in the past 3 months is 5.10.
1OT Financial Forecast
High€-0.06
Consensus€-0.09
Low€-0.13
1OT Earnings Forecast
Next quarter’s earnings estimate for 1OT is -EUR 0.09 with a range of -EUR 0.13 to -EUR 0.06. The previous quarter’s EPS was -EUR 0.09. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€649K
Consensus€65.1K
Low€0.00
1OT Sales Forecast
Next quarter’s sales forecast for 1OT is EUR 65.08K with a range of EUR 0 to EUR 649.02K. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1OT Stock Forecast FAQ
What is DE:1OT’s average 12-month price target, according to analysts?
Based on analyst ratings, Ovid Therapeutics’s 12-month average price target is €5.10.
What is DE:1OT’s upside potential, based on the analysts’ average price target?
Ovid Therapeutics has 105.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Ovid Therapeutics a Buy, Sell or Hold?
Ovid Therapeutics has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Ovid Therapeutics’s share price target?
The average share price target for Ovid Therapeutics is €5.10. This is based on 7 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €6.33, and the lowest forecast is €3.62. The average share price target represents a 105.68% increase from the current price of €2.48.
What do analysts say about Ovid Therapeutics?
Ovid Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Street analysts.
How can I buy shares of Ovid Therapeutics?
To buy shares of DE:1OT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
